Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of Familial Amyloidotic Polyneuropathy.

Biochimica et biophysica acta - 1 Sept 2008

Macedo Bárbara, Batista Ana Rita, Ferreira Nelson, Almeida Maria Rosário, Saraiva Maria João

Abstract excerpt

Tauroursodeoxycholic acid (TUDCA) is a unique natural compound that acts as a potent anti-apoptotic and anti-oxidant agent, reducing cytotoxicity in several neurodegenerative diseases. Since oxidative stress, apoptosis and inflammation are associated with transthyretin (TTR) deposition in Familial Amyloidotic Polyneuropathy (FAP), we investigated the possible TUDCA therapeutical application in this disease. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid Neuropathies, Familial
Share to Endoplasmic Reticulum Chaperone BiP

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to fas Receptor

Share to Gastrointestinal Tract

Share to Heat-Shock Proteins

Share to Methionine

Share to Prealbumin

Share to Protein Structure, Quaternary

Source

Identifiers

PMID: 18572024
DOI: 10.1016/j.bbadis.2008.05.005

Genes

TTR
FAP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of Familial Amyloidotic Polyneuropathy.PMID 18572024Read ↗

Epigallocatechin-3-Gallate as a Potential Therapeutic Drug for TTR-Related Amyloidosis: “In Vivo” Evidence from FAP Mice ModelsSemantic proximity Read ↗

Familial amyloidotic polyneuropathy: protein aggregation in the peripheral nervous system.Semantic proximity Read ↗

Cellular consequences of transthyretin deposition.Semantic proximity Read ↗

Tauroursodeoxycholic acid modulates p53-mediated apoptosis in Alzheimer's disease mutant neuroblastoma cells.Semantic proximity Read ↗

Stability of the transthyretin molecule as a key factor in the interaction with a-beta peptide--relevance in Alzheimer's disease.Semantic proximity Read ↗

Contributions of Animal Models to the Mechanisms and Therapies of Transthyretin AmyloidosisSemantic proximity Read ↗

Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture.Semantic proximity Read ↗

Transthyretin and the brain re-visited: Is neuronal synthesis of transthyretin protective in Alzheimer's disease?Semantic proximity Read ↗

Targeting Amyloid Aggregation: An Overview of Strategies and MechanismsSemantic proximity Read ↗

Inhibition of the Amyloidogenesis of Transthyretin by Natural Products and Synthetic Compounds.Semantic proximity Read ↗

Transduced Tat-DJ-1 Protein Protects against Oxidative Stress-Induced SH-SY5Y Cell Death and Parkinson Disease in a Mouse ModelSemantic proximity Read ↗

Inhibition of TTR aggregation-induced cell death--a new role for serum amyloid P component.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.